Arsanis is preparing for Phase 1 start with ASN100 - a cocktail of two human monoclonal antibodies targeting Staphylococcus aureus - in the fall of 2015.
Arsanis recruited Dr. Rene Russo (former VP of Global Medical Affairs at Cubist) as Chief Development Officer.
Arsanis opens a Boston office and builds a clinical development team.